OnKure Therapeutics (OKUR) Total Non-Current Liabilities (2021 - 2026)
OnKure Therapeutics' (OKUR) quarterly Total Non-Current Liabilities came in at $7.2 million in Q2 2026, down 8.02% on a YoY basis from $7.9 million in Q2 2025, and down 49.52% quarter-over-quarter from $14.3 million in Q1 2026.
Powered by 
Analysis
OnKure Therapeutics (OKUR) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has reported Total Non-Current Liabilities for 3 consecutive years, with $7.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Non-Current Liabilities fell 8.02% year-over-year to $7.2 million; the trailing twelve-month figure through Jun 2026 stood at $7.2 million (down 8.02% YoY), and the FY2025 full-year result was $5.9 million, changed N/A from the prior year.
- Total Non-Current Liabilities declined to $7.2 million in Q2 2026 per OKUR's latest filing, from $14.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $14.3 million in Q1 2026 and bottomed at $5.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 378.37 Mn |
| 10 | OnKure Therapeutics | 162.57 Mn | -13.81 Mn | - | 7.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.23 Mn |
| Mar 31, 2026 | 14.33 Mn |
| Dec 31, 2025 | 5.92 Mn |
| Sep 30, 2025 | 6.37 Mn |
| Jun 30, 2025 | 7.86 Mn |
| Mar 31, 2025 | 9.19 Mn |
| Dec 31, 2021 | 6.65 Mn |